GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
GSK PHARMA Mar-19 |
MYLAN Dec-18 |
GSK PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,595 | 3,561 | - | |
Low | Rs | 1,253 | 1,960 | - | |
Sales per share (Unadj.) | Rs | 184.7 | 1,638.8 | - | |
Earnings per share (Unadj.) | Rs | 26.3 | 44.5 | - | |
Cash flow per share (Unadj.) | Rs | 29.2 | 351.3 | - | |
Dividends per share (Unadj.) | Rs | 20.00 | 0 | - | |
Dividend yield (eoy) | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 126.3 | 1,772.8 | - | |
Shares outstanding (eoy) | m | 169.40 | 514.50 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 13.1 | 1.7 | 779.2% | |
Avg P/E ratio | x | 92.2 | 62.0 | 148.6% | |
P/CF ratio (eoy) | x | 83.1 | 7.9 | 1,057.8% | |
Price / Book Value ratio | x | 19.2 | 1.6 | 1,232.2% | |
Dividend payout | % | 76.1 | 0 | - | |
Avg Mkt Cap | Rs m | 410,626 | 1,420,461 | 28.9% | |
No. of employees | `000 | 5.0 | 35.0 | 14.2% | |
Total wages/salary | Rs m | 5,372 | 0 | - | |
Avg. sales/employee | Rs Th | 6,306.7 | 24,089.9 | 26.2% | |
Avg. wages/employee | Rs Th | 1,083.1 | 0 | - | |
Avg. net profit/employee | Rs Th | 898.0 | 654.1 | 137.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 31,281 | 843,147 | 3.7% | |
Other income | Rs m | 1,023 | 0 | - | |
Total revenues | Rs m | 32,304 | 843,147 | 3.8% | |
Gross profit | Rs m | 6,009 | 218,175 | 2.8% | |
Depreciation | Rs m | 486 | 157,870 | 0.3% | |
Interest | Rs m | 6 | 40,552 | 0.0% | |
Profit before tax | Rs m | 6,540 | 19,752 | 33.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 287 | 0 | - | |
Tax | Rs m | 2,373 | -3,142 | -75.5% | |
Profit after tax | Rs m | 4,454 | 22,895 | 19.5% | |
Gross profit margin | % | 19.2 | 25.9 | 74.2% | |
Effective tax rate | % | 36.3 | -15.9 | -228.1% | |
Net profit margin | % | 14.2 | 2.7 | 524.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 20,061 | 470,812 | 4.3% | |
Current liabilities | Rs m | 14,543 | 343,274 | 4.2% | |
Net working cap to sales | % | 17.6 | 15.1 | 116.6% | |
Current ratio | x | 1.4 | 1.4 | 100.6% | |
Inventory Days | Days | 57 | 84 | 67.9% | |
Debtors Days | Days | 14 | 93 | 15.1% | |
Net fixed assets | Rs m | 14,343 | 163,557 | 8.8% | |
Share capital | Rs m | 1,694 | 449 | 377.4% | |
Net worth | Rs m | 21,398 | 912,131 | 2.3% | |
Long term debt | Rs m | 2 | 984,482 | 0.0% | |
Total assets | Rs m | 39,113 | 2,446,689 | 1.6% | |
Interest coverage | x | 1,091.0 | 1.5 | 73,365.0% | |
Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
Sales to assets ratio | x | 0.8 | 0.3 | 232.1% | |
Return on assets | % | 11.4 | 2.6 | 439.7% | |
Return on equity | % | 20.8 | 2.5 | 829.3% | |
Return on capital | % | 31.9 | 3.2 | 1,004.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,994 | 175,206 | 2.3% | |
From Investments | Rs m | -1,433 | -90,562 | 1.6% | |
From Financial Activity | Rs m | -3,584 | -81,621 | 4.4% | |
Net Cashflow | Rs m | -1,023 | 1,452 | -70.5% |
Compare GSK PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare GSK PHARMA With: ELDER PHARMA ALEMBIC PHARMA VENUS REMEDIES CIPLA IPCA LABS
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More